Prostate Cancer Therapy Using Docetaxel and Formononetin Combination: Hyaluronic Acid and Epidermal Growth Factor Receptor Targeted Peptide Dual Ligands Modified Binary Nanoparticles to Facilitate the in vivo Anti-Tumor Activity

OBJECTIVE: To evaluate the prostate cancer therapy efficiency of the synergistic combination docetaxel (DTX) and formononetin (FMN) in one nano-sized drug delivery system. Hyaluronic acid (HA) and epidermal growth factor receptor-targeted peptide (GE11) dual ligands were applied to modify the nano-s...

Descripción completa

Detalles Bibliográficos
Autores principales: Dong, Zhaoqiang, Wang, Yuzhen, Guo, Jing, Tian, Chuan, Pan, Wengu, Wang, Hongwei, Yan, Jieke
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9380734/
https://www.ncbi.nlm.nih.gov/pubmed/35983428
http://dx.doi.org/10.2147/DDDT.S366622

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9380734/
https://www.ncbi.nlm.nih.gov/pubmed/35983428
http://dx.doi.org/10.2147/DDDT.S366622

Ejemplares similares